Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells

Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities

(2015) Vivien Landré et al.   Oncotarget

FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX

(2014) X. Ling et al.   CANCER RESEARCH

Identification of Clinically Viable Quinolinol Inhibitors of Botulinum Neurotoxin A Light Chain

(2014) Dejan Caglič et al.   JOURNAL OF MEDICINAL CHEMISTRY

Therapeutic Efficacy of p53 Restoration in Mdm2 -Overexpressing Tumors

(2014) Qin Li et al.   MOLECULAR CANCER RESEARCH

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

(2013) Yong S. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

(2013) Zhuming Zhang et al.   ACS Medicinal Chemistry Letters

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy

(2012) Q. Li et al.   CLINICAL CANCER RESEARCH

Mdm2 and MdmX partner to regulate p53

(2012) Xinjiang Wang et al.   FEBS LETTERS

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas

(2012) Angela M Sosin et al.   Journal of Hematology & Oncology

MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular Stress

(2012) L. Biderman et al.   MOLECULAR AND CELLULAR BIOLOGY

MDM4 is a key therapeutic target in cutaneous melanoma

(2012) Agnieszka Gembarska et al.   NATURE MEDICINE

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

(2012) B. Graves et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

(2011) D. Garcia et al.   GENES & DEVELOPMENT

MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination

(2011) Xinjiang Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

(2011) V. Pant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo

(2011) L. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay

(2011) A. G. Herman et al.   Cancer Discovery

Daxx is reciprocally regulated by Mdm2 and Hausp

(2010) Jun Tang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Principles of early drug discovery

(2010) JP Hughes et al.   BRITISH JOURNAL OF PHARMACOLOGY

Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination

(2010) Hanna Berglind et al.   CANCER BIOLOGY & THERAPY

Identification and Biochemical Characterization of Small-Molecule Inhibitors of Clostridium botulinum Neurotoxin Serotype A

(2009) V. Roxas-Duncan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increased Radioresistance and Accelerated B Cell Lymphomas in Mice with Mdmx Mutations that Prevent Modifications by DNA-Damage-Activated Kinases

(2009) Yunyuan V. Wang et al.   CANCER CELL

Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?

(2009) Mark Wade et al.   MOLECULAR CANCER RESEARCH

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans

(2008) K Linke et al.   CELL DEATH AND DIFFERENTIATION

Discovery of a new family of bis-8-hydroxyquinoline substituted benzylamines with pro-apoptotic activity in cancer cells: Synthesis, structure–activity relationship, and action mechanism studies

(2008) Vincent Moret et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY